Exploring the Utility of Whole-Genome Sequencing for the Diagnosis and Management of White Matter Disorders**
Sponsored By: Illumina
Date/Time: Monday, October 18, 2021 - 7:45 PM – 8:45 PM
Log in to Add to My Schedule
This session will provide an overview of the current state of WGS and transcriptomics for neurological disorders and discuss the impact results can have on clinical management and long-term outcomes. The presenters will review interim data from an observational study that implemented WGS as a first-tier test in patients with leukodystrophy and provide an overview of the next phase of that study which will evaluate clinical utility up to six months after results.
- Kayla J. Muirhead, MS, LCGC; Children’s Hospital of Philadelphia
- Holly Snyder, MS, LCGC; Illumina, Inc.
- Ryan Taft, PhD; Illumina, Inc.